LearnGlossaryMarketStocksSuperinvestorsSign in

MYGN

Myriad Genetics, Inc.

Healthcare · $301M market cap

Verdict

We can't put a fair value on MYGN right now. Its free cash flow is negative right now, and this cash-flow valuation needs positive cash flow to start from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth-1.6% a year✗
Equity per share growth5.4% a year✗
Sales growth5.5% a year✗
Free cash flow growth-5.3% a year✗
Return on invested capital-11.7%✗

Follow MYGN

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 3, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Fox Jennifer Lynne

Chief Legal Officer · 2026-09-03

Tax withholding

$14K

About Myriad Genetics, Inc.

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic…

Medical - Diagnostics & Research

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works